Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) shares fell 3% on Friday. The stock traded as low as $2.50 and was last seen at $2.62. About 64,805 shares traded hands during trading, an increase of 18% from the average daily volume of 54,724 shares. The stock had previously closed at $2.70.
Analysts set new price targets
CANF has been the subject of numerous research reports. StockNews.com began coverage on shares of Can-Fite BioPharma in a research note on Friday, July 19th. They gave the stock a “hold” rating. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Can-Fite BioPharma in a research report on Thursday, May 9th. Finally, EF Hutton Acquisition Co. I upgraded shares of Can-Fite BioPharma to a “strong-buy” rating in a research note on Wednesday, July 17th.
Check out our latest research report on CANF
Can-Fite BioPharma trading down 3.0%
The company has a market cap of $9.27 million, a P/E ratio of -1.46 and a beta of 1.45. The stock’s 50-day moving average is $2.99 and its 200-day moving average is $2.44.
Institutional investors comment on Can-Fite BioPharma
An institutional investor recently acquired a new position in shares of Can-Fite BioPharma. Armistice Capital LLC acquired a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 154,363 shares of the company’s stock valued at approximately $340,000. Armistice Capital LLC owned about 4.36% of Can-Fite BioPharma, according to its most recent filing with the Securities & Exchange Commission. Institutional investors own 21.00% of the company’s stock.
About Can-Fite BioPharma
(Get free report)
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, is developing small molecule therapeutic products for the treatment of cancer, inflammatory liver diseases and erectile dysfunction. The company’s lead drug candidate, piclidenoson, has completed Phase III clinical trial for the treatment of psoriasis and Phase II clinical trial for the treatment of COVID-19.
Recommended Stories
Get daily news and reviews for Can-Fite BioPharma – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Can-Fite BioPharma and related companies with MarketBeat.com’s FREE daily email newsletter.
